Decreased serum anti-Müllerian hormone levels in girls with newly diagnosed cancer

Human Reproduction

Volumn 29, Issue 2, 2014, Pages 337-342

  Van Dorp, W ^a,b   Van Den Heuvel Eibrink, M M ^b   De Vries, A C H ^b   Pluijm, S M F ^b   Visser, J A ^a   Pieters, R ^b   Laven, J S E ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b SOPHIA CHILDREN S HOSPITAL   (Netherlands)

Author keywords

Anti M llerian hormone; Childhood cancer; Girls; Pretreatment

Indexed keywords

C REACTIVE PROTEIN; HEMOGLOBIN; MUELLERIAN INHIBITING FACTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; CANCER DIAGNOSIS; CANCER THERAPY; CASE CONTROL STUDY; CHILD; CHILDHOOD CANCER; CONTROLLED STUDY; EARLY CANCER; FEMALE; HEALTH STATUS; HEMOGLOBIN BLOOD LEVEL; HODGKIN DISEASE; HORMONE BLOOD LEVEL; HUMAN; INFANT; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; NEPHROBLASTOMA; NEUROBLASTOMA; NEWBORN; NONHODGKIN LYMPHOMA; OVARY CANCER; OVARY FUNCTION; PRESCHOOL CHILD; PROTEIN BLOOD LEVEL; SARCOMA; SCHOOL CHILD; TEMPERATURE; YOUNG ADULT;

ANTI-MÜLLERIAN HORMONE; CHILDHOOD CANCER; GIRLS; PRETREATMENT;

ADOLESCENT; ANTI-MULLERIAN HORMONE; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; NEOPLASMS;

EID: 84893089627     PISSN: 02681161     EISSN: 14602350     Source Type: Journal    
DOI: 10.1093/humrep/det442     Document Type: Article

References (34)

1. Brougham MF, Crofton PM, Johnson EJ, Evans N, Anderson RA, Wallace WH. Anti-Mullerian hormone is a marker of gonadotoxicity in pre- and postpubertal girls treated for cancer: A prospective study. J Clin Endocrinol Metab 2012;97:2059-2067.
2. de Vet A, Laven JS, de Jong FH, Themmen AP, Fauser BC. Antimullerian hormone serum levels: A putative marker for ovarian aging. Fertil Steril 2002;77:357-362.
3. Dillon KE, Sammel MD, Prewitt M, Ginsberg JP, Walker D, Mersereau JE, Gosiengfiao Y, Gracia CR. Pretreatment antimullerian hormone levels determine rate of posttherapy ovarian reserve recovery: Acute changes in ovarian reserve during and after chemotherapy. Fertil Steril 2012; 99:477-483.
4. Dorman JS, Steenkiste AR, Foley TP, Strotmeyer ES, Burke JP, Kuller LH, Kwoh CK, Familial A, Diabetes S. Menopause in type 1 diabetic women: Is it prematuré. Diabetes 2001;50:1857-1862.
5. Fabbri R, Pasquinelli G, Magnani V, Arpinati M, Battaglia C, Paradisi R, Venturoli S. Follicle features in adolescent and young adult women with Hodgkin's disease prior to chemotherapy: A preliminary report. Reprod Biomed Online 2011;23:799-805.
6. Gast GC, Pop VJ, Samsioe GN, Grobbee DE, Nilsson PM, Keyzer JJ, Wijnands-van Gent CJ, van der Schouw YT. Vasomotor menopausal symptoms are associated with increased risk of coronary heart disease. Menopause 2011;18:146-151.
7. HagenCP, Aksglaede L, Sorensen K, Main KM, Boas M, Cleemann L, Holm K, Gravholt CH, Andersson AM, Pedersen AT. et al.: Serum levels of anti-Mullerian hormone as a marker of ovarian function in 926 healthy females from birth to adulthood and in 172 Turner syndrome patients. J Clin Endocrinol Metab 2010;95:5003-5010.
8. Hagen CP, Aksglaede L, Sorensen K, Mouritsen A, Andersson AM, Petersen JH, Main KM, Juul A. Individual serum levels of anti-Mullerian hormone in healthy girls persist through childhood and adolescence: A longitudinal cohort study. Hum Reprod 2012;27:861-866.
9. Hehenkamp WJ, Looman CW, Themmen AP, de Jong FH, Te Velde ER, Broekmans FJ. Anti-Mullerian hormone levels in the spontaneous menstrual cycle do not show substantial fluctuation. J Clin Endocrinol Metab 2006;91:4057-4063.
10. Hoeijmakers JH. DNA damage, aging, and cancer. N Engl J Med 2009; 361:1475-1485.
11. Howell S, Shalet S. Gonadal damage from chemotherapy and radiotherapy. Endocrinol Metab Clin North Am 1998;27:927-943.
12. Isik S, Ozcan HN, Ozuguz U, Tutuncu YA, Berker D, Alimli AG, Akbaba G, Karademir MA, Guler S. Evaluation of ovarian reserve based on hormonal parameters, ovarian volume, and antral follicle count inwomen with type 2 diabetes mellitus. J Clin Endocrinol Metab 2012;97:261-269.
13. Kelsey TW, Wright P, Nelson SM, Anderson RA, Wallace WH. A validated model of serum anti-mullerian hormone from conception to menopause. PLoS One 2011;6:e22024.
14. Kevenaar ME, Meerasahib MF, Kramer P, van de Lang-Born BM, de Jong FH, Groome NP, Themmen AP, Visser JA. Serum anti-mullerian hormone levels reflect the size of the primordial follicle pool in mice. Endocrinology 2006;147:3228-3234.
15. Kuiri-Hanninen T, Kallio S, Seuri R, Tyrvainen E, Liakka A, Tapanainen J, Sankilampi U, Dunkel L. Postnatal developmental changes in the pituitary-ovarian axis in preterm and term infant girls. J Clin Endocrinol Metab 2011;96:3432-3439.
16. La Marca A, Stabile G, ArtenisioAC, Volpe A. Serum anti-Mullerian hormone throughout the human menstrual cycle.HumReprod 2006;21:3103-3107.
17. Lawrenz B, Henes J, Henes M, Neunhoeffer E, Schmalzing M, FehmT, Kitter I. Impact of systemic lupus erythematosus on ovarian reserve in premenopausal women: Evaluation by using anti-Muellerian hormone. Lupus 2011;20:1193-1197.
18. Lawrenz B, Fehm T, vonWolff M, Soekler M, Huebner S, Henes J, Henes M. Reduced pretreatment ovarian reserve in premenopausal female patients with Hodgkin lymphoma or non-Hodgkin-lymphoma-evaluation by using antimullerianhormoneandretrievedoocytes. Fertil Steril2012;98:141-144.
19. Lie Fong S, Lugtenburg PJ, Schipper I, Themmen AP, de Jong FH, Sonneveld P, Laven JS. Anti-mullerian hormone as a marker of ovarian function in women after chemotherapy and radiotherapy for haematological malignancies. Hum Reprod 2008;23:674-678.
20. Lie Fong S, Laven JS, Hakvoort-Cammel FG, Schipper I, Visser JA, Themmen AP, de Jong FH, van den Heuvel-Eibrink MM. Assessment of ovarian reserve in adult childhood cancer survivors using anti-Mullerian hormone. Hum Reprod 2009;24:982-990.
21. Lie Fong S, Visser JA, Welt CK, de Rijke YB, Eijkemans MJ, Broekmans FJ, Roes EM, Peters WH, Hokken-Koelega AC, Fauser BC. et al.: Serum anti-mullerian hormone levels in healthy females: A nomogram ranging from infancy to adulthood. J Clin Endocrinol Metab 2012;97:4650-4655.
22. McVie JG. Cancer treatment: The last 25 years. Cancer Treat Rev 1999; 25:323-331.
23. Nelson SM, Messow MC, McConnachie A, Wallace H, Kelsey T, Fleming R, Anderson RA, Leader B. External validation of nomogramfor the decline in serum anti-Mullerian hormone in women: A population study of 15, 834 infertility patients. Reprod Biomed Online 2011;23:204-206.
24. Sklar CA, Mertens AC, Mitby P, Whitton J, Stovall M, Kasper C, Mulder J, Green D, Nicholson HS, Yasui Y. et al.: Premature menopause in survivors of childhood cancer: A report from the childhood cancer survivor study. J Natl Cancer Inst 2006;98:890-896.
25. Stolk L, Perry JR, Chasman DI, He C, Mangino M, Sulem P, Barbalic M, Broer L, Byrne EM, Ernst F. et al.: Meta-Analyses identify 13 loci associated with age at menopause and highlight DNA repair and immune pathways. Nat Genet 2012;44:260-268.
26. Streuli I, Fraisse T, Pillet C, Ibecheole V, Bischof P, de Ziegler D. Serum antimullerian hormone levels remain stable throughout the menstrual cycle and after oral or vaginal administration of synthetic sex steroids. Fertil Steril 2008;90:395-400.
27. Tanner JM. Growth and Endocrinology of the Adolescent. Philadelphia: WB Saunders, 1969.
28. Tsepelidis S, Devreker F, Demeestere I, Flahaut A, Gervy C, Englert Y. Stable serum levels of anti-Mullerian hormone during the menstrual cycle: A prospective study in normo-ovulatory women. Hum Reprod 2007; 22:1837-1840.
29. van Casteren NJ, Dohle GR, Romijn JC, de Muinck Keizer-Schrama SM, Weber RF, van den Heuvel-Eibrink MM. Semen cryopreservation in pubertal boys before gonadotoxic treatment and the role of endocrinologic evaluation in predicting sperm yield. Fertil Steril 2008;90:1119-1125.
30. van Casteren NJ, van der Linden GH, Hakvoort-Cammel FG, Hahlen K, Dohle GR, van den Heuvel-Eibrink MM. Effect of childhood cancer treatment on fertility markers in adult male long-Term survivors. Pediatr Blood Cancer 2009;52:108-112.
31. van Dorp W, van Beek RD, Laven JS, Pieters R, de Muinck Keizer-Schrama SM, van den Heuvel-Eibrink MM. Long-Term endocrine side effects of childhood Hodgkin's lymphoma treatment: A review. Hum Reprod Update 2012;18:12-28.
32. Van Dorp W, van den Heuvel-Eibrink MM, Stolk L, Pieters R, Uitterlinden AG, Visser JA, Laven JS. Genetic variation may modify ovarian reserve in female childhood cancer survivors. Hum Reprod 2013; 28:1069-1076.
33. Visser JA, de Jong FH, Laven JS, Themmen AP. Anti-Mullerian hormone: A new marker for ovarian function. Reproduction 2006;131:1-9.
34. Weenen C, Laven JS, Von Bergh AR, Cranfield M, Groome NP, Visser JA, Kramer P, Fauser BC, Themmen AP. Anti-Mullerian hormone expression pattern in the human ovary: Potential implications for initial and cyclic follicle recruitment. Mol Hum Reprod 2004;10:77-83.